Back to today’s briefing

Story perspectives

FDA Boosts Drug Review Process with 15 New Vouchers

11/7/2025

29 3

Summary

Story summary

The U.S. Food and Drug Administration has awarded six additional priority review vouchers, bringing the total to 15.
The vouchers include Eli Lilly's orforglipron and Novo Nordisk's Wegovy, among others.
The program aims to shorten drug-review times from 10–12 months to 1–2 months for products addressing public health needs.
Critics warn the program may favor large pharmaceutical firms and raise post-approval safety or litigation concerns.

1 of 1

Story summary

The U.S. Food and Drug Administration has awarded six additional priority review vouchers, bringing the total to 15.
The vouchers include Eli Lilly's orforglipron and Novo Nordisk's Wegovy, among others.
The program aims to shorten drug-review times from 10–12 months to 1–2 months for products addressing public health needs.
Critics warn the program may favor large pharmaceutical firms and raise post-approval safety or litigation concerns.